These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32587633)

  • 1. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
    Patti F; Visconti A; Capacchione A; Roy S; Trojano M;
    Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
    Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
    Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A; Saccà F; Lanzillo R; Maniscalco GT; Signoriello E; Repice AM; Annovazzi P; Baroncini D; Clerico M; Binello E; Cerqua R; Mataluni G; Perini P; Bonavita S; Lavorgna L; Zarbo IR; Laroni A; Pareja-Gutierrez L; La Gioia S; Frigeni B; Barcella V; Frau J; Cocco E; Fenu G; Clerici VT; Sartori A; Rasia S; Cordioli C; Stromillo ML; Di Sapio A; Pontecorvo S; Grasso R; Barone S; Barrilà C; Russo CV; Esposito S; Ippolito D; Landi D; Visconti A; Sormani MP
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
    Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
    Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T
    Mult Scler; 2021 Mar; 27(3):465-474. PubMed ID: 32530363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y; Wang Y; Wong SL; Yang D; Sundar M; Tundia N
    Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
    Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D; Müller B; Übler S
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
    Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.